Viking Therapeutics Inc (VKTX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Viking Therapeutics Inc stock (VKTX) is currently trading at $33.20. Analyst consensus price target for VKTX is $92.72. WallStSmart rates VKTX as Sell.
- VKTX PE ratio analysis and historical PE chart
- VKTX PS ratio (Price-to-Sales) history and trend
- VKTX intrinsic value — DCF, Graham Number, EPV models
- VKTX stock price prediction 2025 2026 2027 2028 2029 2030
- VKTX fair value vs current price
- VKTX insider transactions and insider buying
- Is VKTX undervalued or overvalued?
- Viking Therapeutics Inc financial analysis — revenue, earnings, cash flow
- VKTX Piotroski F-Score and Altman Z-Score
- VKTX analyst price target and Smart Rating
Viking Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Viking Therapeutics Inc (VKTX) · 5 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around peg ratio and return on equity. Significant fundamental concerns warrant caution or avoidance.
Viking Therapeutics Inc (VKTX) Key Strengths (2)
63.19% held by institutions, strong professional interest
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Viking Therapeutics Inc (VKTX) Areas to Watch (3)
PEG ratio is negative or unavailable
Company is destroying shareholder value
Very expensive at 5.8x book value
Viking Therapeutics Inc (VKTX) Detailed Analysis Report
Overall Assessment
This company scores 14/100 in our Smart Analysis, earning a F grade. Out of 5 metrics analyzed, 2 register as strengths (avg 7.5/10) while 3 fall into concern territory (avg 0.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Market Cap.
The Bear Case
The primary concerns are PEG Ratio, Return on Equity, Price/Book. Some valuation metrics including PEG Ratio (N/A), Price/Book (5.85) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -47.30%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -47.30% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. PEG Ratio and Return on Equity are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
VKTX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
WallStSmart Analysis Synopsis
Data-driven financial summary for Viking Therapeutics Inc (VKTX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Viking Therapeutics Inc operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Free cash flow is -85M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Viking Therapeutics Inc.
Bottom Line
Viking Therapeutics Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(36 last 3 months)
| Insider | Type | Shares |
|---|---|---|
AUBUCHON, NEIL WILLIAM Chief Commercial Officer | Buy | +4,475 |
| Insider | Type | Shares |
|---|---|---|
AUBUCHON, NEIL WILLIAM Chief Commercial Officer | Buy | +180,000 |
Data sourced from SEC Form 4 filings
Last updated: 11:52:43 AM
About Viking Therapeutics Inc(VKTX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing new therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California.